Evolus, Inc. (EOLS): Operating Income
-$32.66M
Year ended 2025-12-31
-$18.67M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$32.66M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$34.41M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$49.23M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | -$65.33M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | -$44.41M | n/m | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | -$153.07M | n/m | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | -$98.95M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$46.14M | n/m | 2020-02-25, From 2018-01-01 |
| 2017-12-31 | -$11.73M | n/a | 2019-03-20, From 2017-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | -$32.66M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $98.50M | +5.8% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $24.90M | n/m |
| CorMedix Inc. (CRMD) | 2025-12-31 | $150.14M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $30.52M | +245.9% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | -$1.05M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $41.00M | n/m |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$118.50M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$166.90M | n/m |
Compare EOLS, IRWD, XERS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗